HalozymeHALO
About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Employees: 350
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
189% more call options, than puts
Call options by funds: $26M | Put options by funds: $8.99M
125% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 9 (+5) [Q1 2025]
90% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 49
34% more repeat investments, than reductions
Existing positions increased: 215 | Existing positions reduced: 161
31% more capital invested
Capital invested by funds: $5.86B [Q4 2024] → $7.66B (+$1.8B) [Q1 2025]
7% more funds holding
Funds holding: 500 [Q4 2024] → 534 (+34) [Q1 2025]
0.91% more ownership
Funds ownership: 96.27% [Q4 2024] → 97.18% (+0.91%) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
HC Wainwright & Co. Mitchell Kapoor | 33%upside $72 | Buy Reiterated | 29 May 2025 |
Morgan Stanley Vikram Purohit | 15%upside $62 | Equal-Weight Downgraded | 14 May 2025 |
Leerink Partners | 13%downside $47 | Underperform Downgraded | 13 May 2025 |
Wells Fargo Mohit Bansal | 20%upside $65 | Equal-Weight Maintained | 7 May 2025 |
JP Morgan Jessica Fye | 7%upside $58 | Neutral Maintained | 21 Apr 2025 |
Financial journalist opinion
Based on 9 articles about HALO published over the past 30 days
